D T Curiel
About
In The Last Decade
D T Curiel
21 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 63
- Molecular Biology 1.0k
- Genetics 1.0k
- Oncology 660
- Radiology, Nuclear Medicine and Imaging 203
- Biotechnology 171
Countries citing papers authored by D T Curiel
This map shows the geographic impact of D T Curiel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D T Curiel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D T Curiel more than expected).
Fields of papers citing papers by D T Curiel
This network shows the impact of papers produced by D T Curiel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D T Curiel. The network helps show where D T Curiel may publish in the future.
Co-authorship network of co-authors of D T Curiel
This figure shows the co-authorship network connecting the top 25 collaborators of D T Curiel. A scholar is included among the top collaborators of D T Curiel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D T Curiel. D T Curiel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 65 | |
| 2 | 172 | |
| 3 | Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. | 120 |
| 4 | Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. | 63 |
| 5 | A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. | 134 |
| 6 | 164 | |
| 7 | 11 | |
| 8 | 142 | |
| 9 | 97 | |
| 10 | 8 | |
| 11 | 4 | |
| 12 | Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. | 74 |
| 13 | Selective elimination (purging) of contaminating malignant cells from hematopoietic stem cell autografts using recombinant adenovirus. | 26 |
| 14 | Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. | 20 |
| 15 | 21 | |
| 16 | 87 | |
| 17 | Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes. | 11 |
| 18 | Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. | 94 |
| 19 | Addition of a short peptide ligand to the adenovirus fiber protein. | 122 |
| 20 | Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag. | 18 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.